Literature DB >> 9674755

Correlation of platelet Fc gammaRIIA polymorphism in refractory idiopathic (immune) thrombocytopenic purpura.

Y Williams1, S Lynch, S McCann, O Smith, C Feighery, A Whelan.   

Abstract

Fc gammaRIIA, a low affinity receptor for IgG, is a polymorphic molecule: Fc gammaRIIA-HH131, Fc gammaRIIA-HR131 and Fc gammaRIIA-RR131. This polymorphism influences the efficiency of the receptor to bind with IgG2. Recent reports on altered distribution amongst individuals with heparin-induced thrombocytopenia (HIT) prompted us to examine the Fc gammaRIIA polymorphism in a cohort of patients with refractory idiopathic (immune) thrombocytopenic purpura (ITP), in whom severe disease had required them to undergo splenectomy. 29 post splenectomy ITP individuals and 61 normal controls were investigated. Polymerase chain reaction (PCR) and a Southern blotting technique were used to determine the Fc gammaRII polymorphism. Although the distribution of the allotypes of Fc gammaRIIA in the control population was similar to that found in other European studies of Caucasian populations (15 (25%) HH131; 35 (57%) HR131; 11 (18%) RR131), the patient group was skewed towards the RR131 allotype which has least efficiency for IgG2 binding (3 (10%) HH131; 12 (42%) HR131; 14 (48%) RR131; P<0.005). These findings suggest that Fc gammaRIIA polymorphisms may be implicated in the pathophysiology of ITP or may be responsible for modulating the immune response in this heterogeneous autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674755     DOI: 10.1046/j.1365-2141.1998.00802.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  Genetic studies in pediatric ITP: outlook, feasibility, and requirements.

Authors:  Anke K Bergmann; Rachael F Grace; Ellis J Neufeld
Journal:  Ann Hematol       Date:  2010-03-23       Impact factor: 3.673

2.  Distribution of the FcgammaRIIIa 176 F/V polymorphism amongst healthy Chinese, Malays and Asian Indians in Singapore.

Authors:  K T Chong; W F Ho; S H Koo; Peter Thompson; Edmund J D Lee
Journal:  Br J Clin Pharmacol       Date:  2006-09-19       Impact factor: 4.335

Review 3.  Functional and clinical consequences of Fc receptor polymorphic and copy number variants.

Authors:  S Bournazos; J M Woof; S P Hart; I Dransfield
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 4.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

5.  Genetic variation of the Fc gamma receptor 3B gene and association with rheumatoid arthritis.

Authors:  Rute B Marques; Mohamed M Thabet; Stefan J White; Jeanine J Houwing-Duistermaat; Aleida M Bakker; Gert-Jan Hendriks; Alexandra Zhernakova; Tom W Huizinga; Annette H van der Helm-van Mil; Rene E Toes
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

Review 6.  CD16 and CD32 Gene Polymorphisms May Contribute to Risk of Idiopathic Thrombocytopenic Purpura.

Authors:  Jiannan Xu; Liyun Zhao; Yan Zhang; Qingxu Guo; Hui Chen
Journal:  Med Sci Monit       Date:  2016-06-18

Review 7.  Contribution of Human FcγRs to Disease with Evidence from Human Polymorphisms and Transgenic Animal Studies.

Authors:  Caitlin Gillis; Aurélie Gouel-Chéron; Friederike Jönsson; Pierre Bruhns
Journal:  Front Immunol       Date:  2014-05-30       Impact factor: 7.561

Review 8.  Expression, Role, and Regulation of Neutrophil Fcγ Receptors.

Authors:  Yu Wang; Friederike Jönsson
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.